Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

Universitair Ziekenhuis Brussel120 enrolled

Overview

The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).

Patients will be randomized at the outpatient clinic in two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

120

Conditions

Reproductive Endocrinology Fertility Optimal Stimulation Protocol

Interventions

GnRH agonistDRUG

GnRH antagonistDRUG

hP-hMGDRUG

Human chorionic gonadotropinDRUG

induction of final oocyte maturation

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 39 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≤ 39 years the day of oocyte retrieval * BMI ≤ 29 * cycle rank 1 * menstrual cycle 25-36 days * PGD or preimplantation genetic screening (PGS) requested * ICSI * Single embryo transfer (SET) on day 5 Exclusion Criteria: * Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria) * Hormonal disturbances * Endometriosis grade III and IV

Locations (1)

Centre for Reproductive Medicine

Brussels, Belgium

Outcomes

Primary Outcomes

Number of day 3 embryos for biopsy available

Time frame: up to 6 weeks

Secondary Outcomes

Number of mature cumulus-oocyte complexes

Time frame: up to 6 weeks

clinical pregnancy rate

Time frame: up to 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.